Median Technologies · EURONEXT:ALMDT
Median Technologies — Investor Presentation (March 2026)
30 slides from Median Technologies's investor presentation, March 2026
Slide 1: AI-Powered Imaging: New Horizons in Fighting Cancer
AI-Powered Imaging: New Horizons in Fighting Cancer Corporate Update March 2026 MEDIAN TECHNOLOGIES
Slide 2: Important Notice
IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING This presentation contains forward-looking statements within the meaning of applicable securities laws. We may also make written or oral forward-looking statements in our publicly available financial information, press releases and oth
Slide 3: Providing invaluable clinical insights where others only see images
Providing invaluable clinical insights where others only Providing Adding ProvidingseeInvaluable images Clinical More Accurate More Value AI-Driven to Oncology Insights Where Others Diagnosis Clinical Trials Only See Images Leveraging Proprietary AI, Generating More Computer Vision, and Signal AI-Dr
Slide 4: Proven & experienced management team
Proven & experienced management team Fredrik Brag Oran Muduroglu Jean-Christophe Montigny Thomas Bonnefont Nicolas Dano Chief Executive Officer, Founder, Executive Chairman of the Board, Chief Financial Officer Chief Operating Officer & Chief Operating Officer & Board Member Named President of Media
Slide 5: Helping Save the Lives of Patients Through Innovation
Global Business – People Everywhere Need Better Answers to Cancer France U.S. + China 190+ €23.5M Headquarters Subsidiaries Employees 2025 Revenue Strong Scientific and Commercial Validation Helping Save the Lives of Patients 7K+ 150+ 340+ 95+ 2 of 3 Site Network Publications & Clinical Studies Biop
Slide 6: Extracting invaluable clinical insights from patients' medical images
Extracting invaluable clinical insights from patients’ medical images End-to-End CADe/CADx Imaging Services for Oncology Clinical Trials Software as Medical Devices (SaMDs) Enabling earlier detection & characterization of cancer with Empowering biopharma to leverage AI, ML, data mining, unprecedente
Slide 7: Strong momentum from recent business catalysts
Strong momentum from recent business catalysts • Achieved FDA 510(k) clearance & filed CE marking submission • Named Oran Muduroglu as President of Median eyonis Inc. to lead the U.S. launch and scale-up, building on strong foundation of preparation High Commercial • Signed non-exclusive distributio
Slide 8: AI imaging is revolutionizing cancer care
AI imaging is revolutionizing cancer care Median’s next generation AI Software as Medical Devices (SaMD) can diagnose early-stage cancer when it can be cured 8
Slide 9: eyonis: proprietary pan-cancer suite of early diagnostic tests
eyonis: proprietary pan-cancer suite of early diagnostic tests Catching the Unseen – Supporting Radiologists and Clinicians Worldwide in Screening, Early Diagnosis & Treatment of Cancer Widely Applicable Foundational Technology – End-to-End, AI/ML-Based CADe/CADx SaMDs First Commercial Opportunity i
Slide 10: Why target lung cancer screening as eyonis' beachhead market?
Why target lung cancer screening as eyonis' beachhead market? #1 18.6% 14.5M of All Lung Cancer Patients Cancer Killer Worldwide(1) U.S. Eligible Population(3) Survive 5 years(2) 80% 19% of Patients Diagnosed at $10B Of All Cancer Deaths: an Early Stage via LDCT Estimated U.S. TAM(4) 1.8M Deaths Glo
Slide 11: The only FDA approved AI-based SaMD solution for LCS
The only FDA approved AI-based SaMD solution for LCS The Historical Diagnostic Paradigm for LCS is Inefficient X No end-to-end solutions to support radiologists X LCS is done by radiologist alone or aided by detection (high false positive rate) √ Only end-to-end solution X No detection & characteriz
Slide 12: Seamlessly enabling scale-up of lung cancer screening
Seamlessly enabling scale-up of lung cancer screening Workflow Easy-to-use Optimizes radiologist's time Increases workflow standardization Compatible with any CT-scan and any PACS system No manual intervention Greater accuracy & efficiency 12
Slide 13: Supporting health professionals for improved patient outcomes
Supporting health professionals for improved patient outcomes eyonis LCS Sensitivity Specificity Manufacturer Values TP-positive TN-Negative (MV) Cases Detected Cases Detected • Significantly reduces false positives (Malignant) (Benign) and false negatives (missed cancers) Performed to determine eyo
Slide 14: Strong platform validation
Strong platform validation Leveraging Top U.S. & EU-based Academic Clinical Sites 1st Distribution Agreement Signed with Tempus AI Involved in Pivotal Studies + • Integration of eyonis LCS into Tempus Pixel, an FDA-cleared, CE-marked AI-enabled solution that provides advanced analysis, tools, and au
Slide 15: eyonis LCS commercial launch and scale-up in the U.S.
eyonis LCS commercial launch and scale-up in the U.S. Oran Muduroglu to lead Key Pillars of the U.S. Commercial Strategy U.S. Commercialization >3 decades of experience building, Phased launch strategy Build-out of direct Strategic non-exclusive engineering, and scaling enterprise for disciplined na
Slide 16: Existing reimbursement to support launch
Existing reimbursement to support launch • Existing CPT III codes for tissue characterization under CT: 0721T & 0722T • CMS payment for 2 CPTIII codes assigned to New Tech APC 1508 - Level 8 ($601 - $700) Total Medicare Hospital Payment is LDCT $107 + eyonis LCS $650(1) Hospital CPT Code CPT Descrip
Slide 17: Clear growth strategy designed to expand eyonis' reach
Clear growth strategy designed to expand eyonis' reach Increase Presence in U.S. • Additional non-exclusive distribution agreements, IDTF & VA focus • Leverage KOL partnerships to enable thought leadership across LCS programs • Initiate health-economics studies to work towards broader, long-term ins
Slide 18: iCRO
iCRO AI-powered imaging to revolutionize drug development Our central imaging services provide global biopharma customers key data on patient response to therapies from phase I to III oncology studies Our Imaging Lab services drive oncology drug development success with transformative AI insights 18
Slide 19: iCRO: leading imaging services for oncology clinical trials
iCRO: leading imaging services for oncology clinical trials Empowering Sponsors and CROs to Accelerate the Development and Delivery of Life-Saving Cancer Treatments Global Leader in Central and AI Imaging Services Strong Financial Profile for Oncology Clinical Trials • Best-in-class, end-to-end imag
Slide 20: Strong traction with leading biopharma
Strong traction with leading biopharma Global Footprint: 95+ 7K+ Evolution of Oncology Studies Managed by Median vs Phases Across U.S., Europe, Biopharmaceutical Site Network 400 and Asia Clients 342 350 306 6 300 274 286 Preferred Imaging Successful FDA 249 Services Provider to Inspections 250 235
Slide 21: Supported 40+ regulatory drug approvals across numerous indications
Supported 40+ regulatory drug approvals across numerous indications • Nasopharyngeal Carcinoma*2 • Head and Neck • Esophageal • Ovarian Squamous Cell • Nasopharyngeal Carcinoma Carcinoma *4 • Squamous Non-Small • Non-Small Cell Lung • Nasopharyngeal Cell Lung Cancer Cancer*4 Carcinoma*2 • Hepatocell
Slide 22: Well-defined iCRO growth acceleration strategy
Well-defined iCRO growth acceleration strategy Leveraging the Transformative Power of Imaging AI for Drug Development 1 2 3 Collaborations Geographical Operational Focus Strategy Establish AI imaging drug EU/U.S.: be selected as Further profitability development preferred provider by big improvement
Slide 23: Summary Financials
Summary Financials 23
Slide 24: Continued growth while driving operational efficiency
Continued growth while driving operational efficiency • iCRO business has continued to grow despite strong operational improvements – iCRO segment now cash flow positive(1) • eyonis LCS launch to drive further topline acceleration Cash Flow Before Financing Activities Revenue (€ Millions) Backlog (€
Slide 25: Capitalization Overview
Capitalization Overview As of December 31, 2025, cash and cash equivalents at €18.2 million Refinancing Overview • Up to €61.4M refinancing completed in summer Current cash runway extends through: 2025 • August 1st: €23.9M gross capital increase through ABSA issuance (new ordinary Q4:2026 shares acc
Slide 26: Business Highlights
Business Highlights 26
Slide 27: Several features drive business opportunity
Several features drive business opportunity More accurate, earlier AI-driven diagnosis through eyonis LCS for lung cancer is now FDA cleared – large market 1 opportunity, exceptional data and well-formulated commercial strategy, including existing reimbursement Providing invaluable clinical insights
Slide 28: Appendix
Appendix 28
Slide 29: Demonstrated clinical strength through two pivotal studies
Demonstrated clinical strength through two pivotal studies 1- REALITY Standalone Study 2 - RELIVE MRMC Study ClinicalTrials.gov ID: NCT06576232 ClinicalTrials.gov ID: NCT06751576 Study design: Retrospective study, Sample size: Enriched cohort of Study design: Two arm, Sample size: Enriched cohort of
Slide 30: Our Core Values
Our Core Values Leading innovation with purpose Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases. Committing to quality in all we do Be dedicated to quality in everything we do. Quality begins with us and we are committed to it. Sup
Median Technologies — Investor Presentation (March 2026) on 6ix